Source: Shenzhen TV (Shenzhen Media Group), “Shenzhen News” · 2026-10-29
- Patient from
- United States
- Larry Black
- Los Angeles, United States
- Condition
- Advanced gastroesophageal-junction adenocarcinoma with peritoneal metastasis
- Treatment
- Claudin18.2-targeted CAR-T (satri-cel)
- Hospital
- The University of Hong Kong-Shenzhen Hospital (International Medical Center)
- City
- Shenzhen
Before China
Diagnosed about 18 months earlier, Larry had neoadjuvant therapy, surgery and several lines of treatment in the U.S., including zolbetuximab with chemotherapy in July 2026, but the disease kept progressing. A biopsy showed Claudin18.2 expression (2+/3+) in 99% of tumour cells, and his CA19-9 had risen to 8,200 U/mL.
Getting care in China
After China’s NMPA approved satri-cel in June 2026, Larry and his wife Jamie travelled more than 11,600 km from Los Angeles to Shenzhen. He was treated at the International Medical Center of the University of Hong Kong–Shenzhen Hospital by Prof. Pan Hongming’s team.
Timeline
- 1June 2026China’s NMPA approves satri-cel, a Claudin18.2 CAR-T for solid tumours.
- 2July 2026Zolbetuximab plus chemotherapy in the U.S. fails to control the disease.
- 3September 29, 2026CAR-T cells are infused in Shenzhen.
- 4About 10 days later the cytokine reaction is under control; CA19-9 has fallen to 57.6 U/mL and he is discharged.
Outcome
After cytokine release syndrome (fever, leg swelling) was managed with tocilizumab and supportive care, his indicators stabilised in about 10 days. CA19-9 fell from 8,200 to 57.6 U/mL, imaging showed marked shrinkage described as approaching complete remission, and he was discharged. This is one reported case, not a promise of results.
Each story is one person’s reported experience, not a promise of results. Outcomes differ with diagnosis and the individual. This is not medical advice; treatment decisions are made with the treating hospital.
Sources
This story is compiled from the public reports below. Please read the original reports for full detail.